Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2025)

Indivior Pharmaceuticals has reported Current Assets over the past 5 years, most recently at $652.0 million for Q4 2025.

  • Quarterly results put Current Assets at $652.0 million for Q4 2025, down 21.16% from a year ago — trailing twelve months through Dec 2025 was $652.0 million (down 21.16% YoY), and the annual figure for FY2025 was $652.0 million, down 21.16%.
  • Current Assets for Q4 2025 was $652.0 million at Indivior Pharmaceuticals, down from $922.0 million in the prior quarter.
  • Over the last five years, Current Assets for INDV hit a ceiling of $1.4 billion in Q4 2021 and a floor of $652.0 million in Q4 2025.
  • Median Current Assets over the past 5 years was $936.5 million (2025), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Current Assets: decreased 0.16% in 2023 and later plummeted 34.21% in 2024.
  • Indivior Pharmaceuticals' Current Assets stood at $1.4 billion in 2021, then decreased by 12.81% to $1.3 billion in 2022, then dropped by 0.16% to $1.3 billion in 2023, then plummeted by 34.21% to $827.0 million in 2024, then fell by 21.16% to $652.0 million in 2025.
  • The last three reported values for Current Assets were $652.0 million (Q4 2025), $922.0 million (Q3 2025), and $951.0 million (Q2 2025) per Business Quant data.